- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02572986
A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% to Elimite™ Cream 5% in the Treatment of Scabies
Scabies is an infestation of the skin by the human itch mite (Sarcoptes scabiei). Diagnosis of scabies is made based on clinical symptoms, such as nocturnal itching, and appearance and distribution of the rash. Definitive diagnosis includes the microscopic identification of the mite, mite eggs, or mite fecal matter in the skin. Topical permethrin is considered the drug of choice for the treatment of scabies. It is a synthetic pyrethroid that is safe for use in adults and children 2 months and older.
This study will evaluate the therapeutic equivalence of a generic permethrin cream 5% to Elimite® in the Treatment of Scabies.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
San Salvador, El Salvador
- Clinica Dermatologica
-
Santa Tecla, La Libertad, El Salvador
- Clinica Dermatologica y Cirugia de Piel
-
-
-
-
PanamaCity
-
Ciudad de Panama, PanamaCity, Panama
- Clinica Dermatologica Dra. Yariela Grajales
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- Omni Dermatology
-
-
California
-
Bell Gardens, California, United States, 90201
- Sun Rise Clinical Research, Inc
-
Pasadena, California, United States, 91105
- Havana Research Institute
-
-
Florida
-
Jacksonville, Florida, United States, 32258
- Solutions Through Advanced Research
-
Miami, Florida, United States, 33176
- Vista Health Research, LLC
-
Miami, Florida, United States, 33015
- San Marcus Research Clinic, Incorporation
-
Miami, Florida, United States, 33144
- L & C Professional Medical Research Institute
-
-
Pennsylvania
-
Hazleton, Pennsylvania, United States, 18201
- Derm Dx Center for Dermatology
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Sun Research Institute
-
-
Washington
-
Richland, Washington, United States, 99352
- Zain Research, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent that meets all criteria of current FDA regulations.
- Male or non-pregnant, non-lactating female at least 2 years of age or older.
- Diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions at the classic sites of infestation.
- Parasitological confirmation of clinical diagnosis with demonstration under light microscope of mites and/or their products (larvae, eggs or fecal material).
- Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching.
Women must be either 1 year post-menopausal (no menstrual periods for at least 12 months), surgically sterile, or if they are of child-bearing potential, they must:
- Have been using systemic birth control, intrauterine device, or used barrier methods such as diaphragm plus spermicide or condom plus spermicide consistently, at least 14 days before study cream administration.
- Had a normal menstrual cycle for the month before start of treatment.
- Have a negative urine pregnancy test result upon entry into the study.
- Agree to use a medically accepted form of birth control (oral, implant, injectable or transdermal contraceptives, intrauterine device, condom plus spermicide, diaphragm plus spermicide) or practice abstinence throughout the study period.
- Free from any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events.
- Ability to apply study product to self or to other person if a child. If patient is a child, then parent/guardian will apply study product to him/her.
Exclusion Criteria:
- Known hypersensitivity to permethrin cream or any of its components, ragweed or chrysanthemums, synthetic pyrethroids or pyrethrin.
- Use of any systemic or topical acaricide 1 month before enrollment.
- Patients with crusted/Norwegian scabies.
- Patients with an underlying immunodeficient state (including prolonged treatment with corticosteroids), immunosuppressive disorders requiring therapy, severe systemic disease and history of HIV infection.
- Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.
- Women who are pregnant, planning pregnancy or lactating.
- Family members of employees of the clinic or Investigator.
- Patients who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.
- Patients whose close personal contacts will not or are not willing to comply with standard of care for Scabies management.
- Patients less than 2 years of age.
- Patients or guardians of patients, who are unable or unwilling to give informed consent or assent respectively.
- Receipt of any drug as part of a research study within 30 days before screening.
- History of seizures.
- Severe cutaneous bacterial or fungal infections requiring therapy (including systemic and topical antibiotics) or coexisting dermatological disorder that could interfere with the diagnosis and subsequent monitoring of scabies.
- Treatment with systemic or topical corticosteroids less than 2 weeks and less than 1 week from enrollment, respectively.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Permethrin cream 5%
Manufactured by Dr. Reddy's Laboratories, Ltd
|
|
Active Comparator: Elimite™ Cream (permethrin) 5%
Manufactured by Prestium Pharma, Inc
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with therapeutic cure (parasitological cure plus clinical cure) of scabies
Time Frame: Day 28
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients with no itch persistence
Time Frame: Day 28
|
Day 28
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events assessment
Time Frame: Day 28
|
Day 28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Ashis Patnaik, MD, Dr. Reddy's Laboratories Limited
- Study Director: Prasanna Ganapathi, MD, Dr. Reddy's Laboratories Limited
- Study Director: Shilpi Dhawan, MD, Dr. Reddy's Laboratories Limited
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DRL-USG02-P/2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scabies
-
Assistance Publique - Hôpitaux de ParisCompletedIvermectin | Gale | Severe Forms of Scabies | Oral Parasitic DrugFrance
-
Murdoch Childrens Research InstituteBurnet Institute; Lao Tropical and Public Health InstituteActive, not recruitingScabies | Scabies; ItchLao People's Democratic Republic
-
ParaPRO LLCIqvia Pty Ltd; Medpace, Inc.; Concentrics Research; Inotiv Laboratories; BioAgilytixRecruiting
-
Medicines Development for Global HealthCompleted
-
Mylan Inc.Vyne Therapeutics Inc.; DPT Laboratories, Ltd.CompletedScabiesUnited States, Dominican Republic, Honduras, Puerto Rico
-
Mayne Pharma International Pty LtdbioRASI, LLCCompleted
-
Edward Via Virginia College of Osteopathic MedicineCompleted
-
Medicines Development for Global HealthRecruiting
-
Centre Hospitalier de CayenneRecruiting
-
University of OxfordKenya Medical Research Institute; Fundação Alfredo da Matta (FUAM); Fundação... and other collaboratorsRecruiting
Clinical Trials on Permethrin
-
London School of Hygiene and Tropical MedicineFederal Minstry of Health of Ethiopia; Oromia Regional Health Bureau, Ethiopia and other collaboratorsCompletedTrachomaUnited Kingdom, Ethiopia
-
Assistance Publique Hopitaux De MarseilleTerminated
-
Mylan Inc.Vyne Therapeutics Inc.; DPT Laboratories, Ltd.CompletedScabiesUnited States, Dominican Republic, Honduras, Puerto Rico
-
Saptalis Pharmaceuticals LLCbioRASI, LLCCompleted
-
Encube Ethicals Pvt. Ltd.Novum Pharmaceutical Research ServicesCompletedScabiesUnited States, El Salvador, Puerto Rico
-
University of North Carolina, Chapel HillNorth Carolina State UniversityCompleted
-
Mayne Pharma International Pty LtdbioRASI, LLCCompleted
-
Umeå UniversityEuropean UnionTerminated
-
B.P. Koirala Institute of Health SciencesCompleted
-
University of North Carolina, Chapel HillNational Institute for Occupational Safety and Health (NIOSH/CDC); East Carolina... and other collaboratorsCompletedTick Bites | Tick-borne DiseasesUnited States